5,685 Shares in Surmodics, Inc. (NASDAQ:SRDX) Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in shares of Surmodics, Inc. (NASDAQ:SRDX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,685 shares of the company’s stock, valued at approximately $220,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lazard Asset Management LLC increased its position in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after purchasing an additional 673 shares in the last quarter. BNP Paribas Financial Markets increased its position in Surmodics by 7.5% during the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after purchasing an additional 481 shares in the last quarter. Hardin Capital Partners LLC purchased a new stake in Surmodics in the 2nd quarter valued at about $206,000. Mesirow Financial Investment Management Inc. purchased a new stake in Surmodics in the 1st quarter valued at about $223,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Surmodics in the 2nd quarter valued at about $229,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SRDX. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Monday, August 5th. StockNews.com began coverage on Surmodics in a report on Tuesday. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Performance

NASDAQ SRDX opened at $38.28 on Wednesday. The firm has a market capitalization of $545.87 million, a P/E ratio of 40.29 and a beta of 1.20. Surmodics, Inc. has a 1-year low of $25.17 and a 1-year high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22. The business’s 50-day simple moving average is $39.09 and its 200-day simple moving average is $37.77.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04. The business had revenue of $30.34 million for the quarter, compared to analyst estimates of $30.32 million. Surmodics had a positive return on equity of 3.88% and a negative net margin of 1.16%. Equities analysts predict that Surmodics, Inc. will post -0.47 EPS for the current year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).